Author | Tomohiko Ohta, MD

Articles

Combination Therapy for Advanced Breast Cancer: Cyclophosphamide, Doxorubicin, UFT, and Tamoxifen

July 01, 1999

ByMamoru Fukuda, MD

Susumu Yamaguchi, MD

Tomohiko Ohta, MD

Yoshiaki Nakayama, MD

We evaluated combination therapy for advanced and recurrent breast cancer with cyclophosphamide (Cytoxan), doxorubicin (Adriamycin), uracil and tegafur (UFT), and tamoxifen (Nolvadex) (CAUT), designed as